FDA approves expansion of cancer drug use

Welireg (belzutifan), a Merck drug co-developed by researchers at Dallas-based UT Southwestern Medical Center, gained a new approval Dec. 14.

Based on work that began in the 1990s, UT Southwestern researchers "solved the HIF-2α protein structure, pinpointing a potential vulnerability" in the gene, according to a news release from the medical center. 

The researchers then formed Peloton Therapeutics to develop and test belzutifan. Merck acquired Peloton in 2019, and the FDA approved the drug for a familial kidney cancer condition in 2021. About two years later, the approved label grew to include anyone with advanced renal cell carcinoma — the most common type of kidney cancer.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like